Acute effects of haemodialysis on biochemical modulators of endothelial function

Journal of Internal Medicine

Volumn 262, Issue 5, 2007, Pages 571-580

  Hewitson, C L ^b   Whiting, M J ^b   Barbara, J A ^b   Mangoni, A A ^a,b  

^a FLINDERS UNIVERSITY   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

Asymmetric dimethylarginine; Endothelial function; Folic acid; Haemodialysis; Homocysteine

Indexed keywords

C REACTIVE PROTEIN; FOLIC ACID; GLYCERYL TRINITRATE; HOMOCYSTEINE; MALONALDEHYDE; N(G),N(G) DIMETHYLARGININE; SALBUTAMOL;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; FOLIC ACID BLOOD LEVEL; HEALTH CARE FACILITY; HEMODIALYSIS; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; TONOMETRY; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASODILATATION;

ARGININE; BLOOD PRESSURE; C-REACTIVE PROTEIN; ENDOTHELIUM, VASCULAR; FEMALE; FOLIC ACID; HEART RATE; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MALONDIALDEHYDE; MIDDLE AGED; RENAL DIALYSIS; VASODILATION;

EID: 35448975252     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2007.01848.x     Document Type: Article

References (46)

1. Covic A, Gusbeth-Tatomir P, Goldsmith DJ. The challenge of cardiovascular risk factors in end-stage renal disease. J Nephrol 2003 16 : 476 86.
2. Foley RN. Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin Dial 2003 16 : 111 7.
3. Annuk M, Zilmer M, Fellstrom B. Endothelium-dependent vasodilation and oxidative stress in chronic renal failure: impact on cardiovascular disease. Kidney Int Suppl 2003 84 : S50 3.
4. Nakanishi T, Ishigami Y, Otaki Y et al. Impairment of vascular responses to reactive hyperemia and nitric oxide in chronic renal failure. Nephron 2002 92 : 529 35.
5. Wever R, Boer P, Hijmering M et al. Nitric oxide production is reduced in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 1999 19 : 1168 72.
6. Bian K, Murad F. Nitric oxide (NO) - biogeneration, regulation, and relevance to human diseases. Front Biosci 2003 8 : d264 78.
7. Wilkinson IB, MacCallum H, Cockcroft JR, Webb DJ. Inhibition of basal nitric oxide synthesis increases aortic augmentation index and pulse wave velocity in vivo. Br J Clin Pharmacol 2002a 53 : 189 92.
8. London GM, Pannier B, Agharazii M, Guerin AP, Verbeke FH, Marchais SJ. Forearm reactive hyperemia and mortality in end-stage renal disease. Kidney Int 2004 65 : 700 4.
9. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999 99 : 2434 9.
10. London GM, Marchais SJ, Guerin AP, Metivier F. Impairment of arterial function in chronic renal disease: prognostic impact and therapeutic approach. Nephrol Dial Transplant 2002 17 (Suppl. 11 13 5.
11. Wilkinson IB, Hall IR, MacCallum H et al. Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function. Arterioscler Thromb Vasc Biol 2002b 22 : 147 52.
12. Woo KS, Chook P, Lolin YI et al. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997 96 : 2542 4.
13. Nestel PJ, Chronopoulos A, Cehun M. Arterial stiffness is rapidly induced by raising the plasma homocysteine concentration with methionine. Atherosclerosis 2003 171 : 83 6.
14. Boger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the 'L-arginine paradox' and acts as a novel cardiovascular risk factor. J Nutr 2004 10 (Suppl. 2842S 7S.
15. Kielstein JT, Donnerstag F, Gasper S et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006 37 : 2024 9.
16. Verma S, Wang CH, Li SH et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002 106 : 913 9.
17. Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockcroft JR, Wilkinson IB. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol 2004 24 : 969 74.
18. Rodriguez-Martinez MA, Martinez-Org J, Salaices M, Marin J. Impairment of acetylcholine relaxations by malondialdehyde, a marker of lipid peroxidation. J Vasc Res 1996 33 : 463 70.
19. Buccianti G, Baragetti I, Bamonti F, Furiani S, Dorighet V, Patrosso C. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease. J Nephrol 2004 17 : 405 10.
20. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005 16 : 2449 55.
21. Zoccali C, Tripepi G, Mallamaci F. Predictors of cardiovascular death in ESRD. Semin Nephrol 2005 25 : 358 62.
22. Yao Q, Pecoits-Filho R, Lindholm B, Stenvinkel P. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol 2004 38 : 405 16.
23. Verhaar MC, Stroes E, Rabelink TJ. Folates and cardiovascular disease. Arterioscler Thromb Vasc Biol 2002 22 : 6 13.
24. Mangoni AA, Sherwood RA, Asonganyi B, Swift CG, Thomas S, Jackson SH. Short-term oral folic acid supplementation enhances endothelial function in patients with type 2 diabetes. Am J Hypertens 2005 18 : 220 6.
25. Covic A, Goldsmith DJ, Gusbeth-Tatomir P, Covic M. Haemodialysis acutely improves ndothelium-independent vasomotor function without significantly influencing the endothelium-mediated abnormal response to a beta 2-agonist. Nephrol Dial Transplant 2004 19 : 637 43.
26. Kosch M, Levers A, Fobker M et al. Dialysis filter type determines the acute effect of haemodialysis on endothelial function and oxidative stress. Nephrol Dial Transplant 2003 18 : 1370 5.
27. McGregor DO, Buttimore AL, Lynn KL, Yandle T, Nicholls MG. Effects of long and short hemodialysis on endothelial function: a short-term study. Kidney Int 2003 63 : 709 15.
28. Arnadottir M, Berg AL, Hegbrant J, Hultberg B. Influence of haemodialysis on plasma total homocysteine concentration. Nephrol Dial Transplant 1999 14 : 142 6.
29. Raj DS, Vincent B, Simpson K et al. Hemodynamic changes during hemodialysis: role of nitric oxide and endothelin. Kidney Int 2002 61 : 697 704.
30. O'Rourke MF, Pauca A, Jiang XJ. Pulse wave analysis. Br J Clin Pharmacol 2001 51 : 507 22.
31. Covic A, Goldsmith DJ, Panaghiu L, Covic M, Sedor J. Analysis of the effect of hemodialysis on peripheral and central arterial pressure waveforms. Kidney Int 2000 57 : 2634 43.
32. Savage MT, Ferro CJ, Pinder SJ, Tomson CR. Reproducibility of derived central arterial waveforms in patients with chronic renal failure. Clin Sci (Lond) 2002 103 : 59 65.
33. Weir JP. Quantifying test-retest reliability using the intraclass correlation coefficient and the SEM. J Strength Cond Res 2005 19 : 231 40.
34. Cornwell PE, Morgan SL, Vaughn WH. Modification of a high-performance liquid chromatographic method for assay of homocysteine in human plasma. J Chromatogr 1993 617 : 136 9.
35. Nielsen F, Mikkelsen BB, Nielsen JB, Andersen HR, Grandjean P. Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin Chem 1997 43 : 1209 14.
36. Moshage H, Kok B, Huizenga JR, Jansen PL. Nitrite and nitrate determinations in plasma: a critical evaluation. Clin Chem 1995 41 : 892 6.
37. Schwedhelm E, Tan-Andresen J, Maas R, Riederer U, Schulze F, Boger RH. Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem 2005 51 : 1268 71.
38. Morris ST, Jardine AG. The vascular endothelium in chronic renal failure. J Nephrol 2000 13 : 96 105.
39. Schwedhelm E. Quantification of ADMA: analytical approaches. Vasc Med 2005 10 (Suppl. 1 S89 95.
40. Gonin JM. Folic acid supplementation to prevent adverse events in individuals with chronic kidney disease and end stage renal disease. Curr Opin Nephrol Hypertens 2005 14 : 277 81.
41. Mangoni AA, Jackson SH. Homocysteine and cardiovascular disease: current evidence and future prospects. Am J Med 2002 112 : 556 65.
42. Mangoni AA. Folic acid, inflammation, and atherosclerosis: false hopes or the need for better trials Clin Chim Acta 2006 367 : 11 9.
43. Hyndman ME, Verma S, Rosenfeld RJ, Anderson TJ, Parsons HG. Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. Am J Physiol Heart Circ Physiol 2002 282 : H2167 72.
44. Antoniades C, Shirodaria C, Warrick N et al. 5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 2006 114 : 1193 201.
45. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004 15 : 420 6.
46. Zoungas S, McGrath BP, Branley P et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol 2006 47 : 1108 16.